3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
3
Diabetes Mellitus
2
Vomiting
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Premature Birth
1
Pre-Eclampsia
1
Polycystic Ovary Syndrome
1
Parathyroid Neoplasms
1
Neoplasms
1
Medulloblastoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Leukemia, B-Cell
1
Leiomyosarcoma
1
Hyperparathyroidism, Primary
1
Hot Flashes
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Erectile Dysfunction
1
Cognitive Dysfunction
1
Carcinoma, Renal Cell
1
Interventions
ofatumumab
3
venetoclax
2
pirtobrutinib
2
obinutuzumab
2
ibrutinib
2
Chlorambucil
2
acalabrutinib
1
Tablets
1
Observation
1
Cholecalciferol
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, B-Cell
×
Tablets
×
Clear all
NCT00748189
2019-06-25
COMPLEMENT 1
Novartis
Phase 3
Terminated
447 enrolled
32 charts